Article
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
Cancer science - 1 Feb 2022
Liu Yingqiang, Lai Mengzhen, Li Shan, Wang Yanan, Feng Fang, Zhang Tao, Tong Linjiang, Zhang Mengge, Chen Hao, Chen Yi, Song Peiran, Li Yan, Bai Gang, Ning Yi, Tang Haotian, Fang Yan, Chen Yi, Lu Xiaoyun, Geng Meiyu, Ding Ke, Yu Ker, Xie Hua, Ding Jian
Abstract excerpt
With the wide clinical use of the third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), acquired resistance caused by EGFR C797S tertiary mutation has become a concern. Therefore, fourth-generation EGFR inhibitors that could overcome this mutation have gained increasing attention in recent years. Here, we identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.